CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis

Sarah M. Greenblatt, Na Man, Pierre Jacques Hamard, Takashi Asai, Daniel Karl, Concepcion Martinez, Daniel Bilbao, Vasileios Stathais, Anna McGrew-Jermacowicz, Stephanie Duffort, Madhavi Tadi, Ezra Blumenthal, Samantha Newman, Ly Vu, Ye Xu, Fan Liu, Stephan C Schuerer, Michael T. McCabe, Ryan G. Kruger, Mingjiang Xu & 5 others Feng-Chun Yang, Daniel Tenen, Justin Watts, Francisco Vega, Stephen D Nimer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Chromatin-modifying enzymes, and specifically the protein arginine methyltransferases (PRMTs), have emerged as important targets in cancer. Here, we investigated the role of CARM1 in normal and malignant hematopoiesis. Using conditional knockout mice, we show that loss of CARM1 has little effect on normal hematopoiesis. Strikingly, knockout of Carm1 abrogates both the initiation and maintenance of acute myeloid leukemia (AML) driven by oncogenic transcription factors. We show that CARM1 knockdown impairs cell-cycle progression, promotes myeloid differentiation, and ultimately induces apoptosis. Finally, we utilize a selective, small-molecule inhibitor of CARM1 to validate the efficacy of CARM1 inhibition in leukemia cells in vitro and in vivo. Collectively, this work suggests that targeting CARM1 may be an effective therapeutic strategy for AML. Greenblatt et al. show that loss of the protein arginine methyltransfersase CARM1 minimally impacts normal hematopoiesis but strongly impairs leukemogenesis by regulating cell-cycle progression, myeloid differentiation, and apoptosis. Targeting CARM1 reduces AML growth in primary patient samples and mouse models.

Original languageEnglish (US)
Pages (from-to)1111-1127.e5
JournalCancer Cell
Volume33
Issue number6
DOIs
StatePublished - Jun 11 2018

Fingerprint

Hematopoiesis
Acute Myeloid Leukemia
Cell Cycle
Protein-Arginine N-Methyltransferases
Apoptosis
coactivator-associated arginine methyltransferase 1
Knockout Mice
Chromatin
Arginine
Leukemia
Transcription Factors
Maintenance
Enzymes
Growth

Keywords

  • acute myeloid leukemia
  • AML
  • AML1-ETO
  • arginine methyltransferase
  • CARM1
  • epigenetics
  • MLL-AF9

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Greenblatt, S. M., Man, N., Hamard, P. J., Asai, T., Karl, D., Martinez, C., ... Nimer, S. D. (2018). CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell, 33(6), 1111-1127.e5. https://doi.org/10.1016/j.ccell.2018.05.007

CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. / Greenblatt, Sarah M.; Man, Na; Hamard, Pierre Jacques; Asai, Takashi; Karl, Daniel; Martinez, Concepcion; Bilbao, Daniel; Stathais, Vasileios; McGrew-Jermacowicz, Anna; Duffort, Stephanie; Tadi, Madhavi; Blumenthal, Ezra; Newman, Samantha; Vu, Ly; Xu, Ye; Liu, Fan; Schuerer, Stephan C; McCabe, Michael T.; Kruger, Ryan G.; Xu, Mingjiang; Yang, Feng-Chun; Tenen, Daniel; Watts, Justin; Vega, Francisco; Nimer, Stephen D.

In: Cancer Cell, Vol. 33, No. 6, 11.06.2018, p. 1111-1127.e5.

Research output: Contribution to journalArticle

Greenblatt, SM, Man, N, Hamard, PJ, Asai, T, Karl, D, Martinez, C, Bilbao, D, Stathais, V, McGrew-Jermacowicz, A, Duffort, S, Tadi, M, Blumenthal, E, Newman, S, Vu, L, Xu, Y, Liu, F, Schuerer, SC, McCabe, MT, Kruger, RG, Xu, M, Yang, F-C, Tenen, D, Watts, J, Vega, F & Nimer, SD 2018, 'CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis', Cancer Cell, vol. 33, no. 6, pp. 1111-1127.e5. https://doi.org/10.1016/j.ccell.2018.05.007
Greenblatt SM, Man N, Hamard PJ, Asai T, Karl D, Martinez C et al. CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell. 2018 Jun 11;33(6):1111-1127.e5. https://doi.org/10.1016/j.ccell.2018.05.007
Greenblatt, Sarah M. ; Man, Na ; Hamard, Pierre Jacques ; Asai, Takashi ; Karl, Daniel ; Martinez, Concepcion ; Bilbao, Daniel ; Stathais, Vasileios ; McGrew-Jermacowicz, Anna ; Duffort, Stephanie ; Tadi, Madhavi ; Blumenthal, Ezra ; Newman, Samantha ; Vu, Ly ; Xu, Ye ; Liu, Fan ; Schuerer, Stephan C ; McCabe, Michael T. ; Kruger, Ryan G. ; Xu, Mingjiang ; Yang, Feng-Chun ; Tenen, Daniel ; Watts, Justin ; Vega, Francisco ; Nimer, Stephen D. / CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. In: Cancer Cell. 2018 ; Vol. 33, No. 6. pp. 1111-1127.e5.
@article{52f3fd6533fa4b36bd69bed18183b86b,
title = "CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis",
abstract = "Chromatin-modifying enzymes, and specifically the protein arginine methyltransferases (PRMTs), have emerged as important targets in cancer. Here, we investigated the role of CARM1 in normal and malignant hematopoiesis. Using conditional knockout mice, we show that loss of CARM1 has little effect on normal hematopoiesis. Strikingly, knockout of Carm1 abrogates both the initiation and maintenance of acute myeloid leukemia (AML) driven by oncogenic transcription factors. We show that CARM1 knockdown impairs cell-cycle progression, promotes myeloid differentiation, and ultimately induces apoptosis. Finally, we utilize a selective, small-molecule inhibitor of CARM1 to validate the efficacy of CARM1 inhibition in leukemia cells in vitro and in vivo. Collectively, this work suggests that targeting CARM1 may be an effective therapeutic strategy for AML. Greenblatt et al. show that loss of the protein arginine methyltransfersase CARM1 minimally impacts normal hematopoiesis but strongly impairs leukemogenesis by regulating cell-cycle progression, myeloid differentiation, and apoptosis. Targeting CARM1 reduces AML growth in primary patient samples and mouse models.",
keywords = "acute myeloid leukemia, AML, AML1-ETO, arginine methyltransferase, CARM1, epigenetics, MLL-AF9",
author = "Greenblatt, {Sarah M.} and Na Man and Hamard, {Pierre Jacques} and Takashi Asai and Daniel Karl and Concepcion Martinez and Daniel Bilbao and Vasileios Stathais and Anna McGrew-Jermacowicz and Stephanie Duffort and Madhavi Tadi and Ezra Blumenthal and Samantha Newman and Ly Vu and Ye Xu and Fan Liu and Schuerer, {Stephan C} and McCabe, {Michael T.} and Kruger, {Ryan G.} and Mingjiang Xu and Feng-Chun Yang and Daniel Tenen and Justin Watts and Francisco Vega and Nimer, {Stephen D}",
year = "2018",
month = "6",
day = "11",
doi = "10.1016/j.ccell.2018.05.007",
language = "English (US)",
volume = "33",
pages = "1111--1127.e5",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis

AU - Greenblatt, Sarah M.

AU - Man, Na

AU - Hamard, Pierre Jacques

AU - Asai, Takashi

AU - Karl, Daniel

AU - Martinez, Concepcion

AU - Bilbao, Daniel

AU - Stathais, Vasileios

AU - McGrew-Jermacowicz, Anna

AU - Duffort, Stephanie

AU - Tadi, Madhavi

AU - Blumenthal, Ezra

AU - Newman, Samantha

AU - Vu, Ly

AU - Xu, Ye

AU - Liu, Fan

AU - Schuerer, Stephan C

AU - McCabe, Michael T.

AU - Kruger, Ryan G.

AU - Xu, Mingjiang

AU - Yang, Feng-Chun

AU - Tenen, Daniel

AU - Watts, Justin

AU - Vega, Francisco

AU - Nimer, Stephen D

PY - 2018/6/11

Y1 - 2018/6/11

N2 - Chromatin-modifying enzymes, and specifically the protein arginine methyltransferases (PRMTs), have emerged as important targets in cancer. Here, we investigated the role of CARM1 in normal and malignant hematopoiesis. Using conditional knockout mice, we show that loss of CARM1 has little effect on normal hematopoiesis. Strikingly, knockout of Carm1 abrogates both the initiation and maintenance of acute myeloid leukemia (AML) driven by oncogenic transcription factors. We show that CARM1 knockdown impairs cell-cycle progression, promotes myeloid differentiation, and ultimately induces apoptosis. Finally, we utilize a selective, small-molecule inhibitor of CARM1 to validate the efficacy of CARM1 inhibition in leukemia cells in vitro and in vivo. Collectively, this work suggests that targeting CARM1 may be an effective therapeutic strategy for AML. Greenblatt et al. show that loss of the protein arginine methyltransfersase CARM1 minimally impacts normal hematopoiesis but strongly impairs leukemogenesis by regulating cell-cycle progression, myeloid differentiation, and apoptosis. Targeting CARM1 reduces AML growth in primary patient samples and mouse models.

AB - Chromatin-modifying enzymes, and specifically the protein arginine methyltransferases (PRMTs), have emerged as important targets in cancer. Here, we investigated the role of CARM1 in normal and malignant hematopoiesis. Using conditional knockout mice, we show that loss of CARM1 has little effect on normal hematopoiesis. Strikingly, knockout of Carm1 abrogates both the initiation and maintenance of acute myeloid leukemia (AML) driven by oncogenic transcription factors. We show that CARM1 knockdown impairs cell-cycle progression, promotes myeloid differentiation, and ultimately induces apoptosis. Finally, we utilize a selective, small-molecule inhibitor of CARM1 to validate the efficacy of CARM1 inhibition in leukemia cells in vitro and in vivo. Collectively, this work suggests that targeting CARM1 may be an effective therapeutic strategy for AML. Greenblatt et al. show that loss of the protein arginine methyltransfersase CARM1 minimally impacts normal hematopoiesis but strongly impairs leukemogenesis by regulating cell-cycle progression, myeloid differentiation, and apoptosis. Targeting CARM1 reduces AML growth in primary patient samples and mouse models.

KW - acute myeloid leukemia

KW - AML

KW - AML1-ETO

KW - arginine methyltransferase

KW - CARM1

KW - epigenetics

KW - MLL-AF9

UR - http://www.scopus.com/inward/record.url?scp=85047524038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047524038&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2018.05.007

DO - 10.1016/j.ccell.2018.05.007

M3 - Article

VL - 33

SP - 1111-1127.e5

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 6

ER -